ArticleMMWR. Morbidity and mortality weekly report2013
Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.
Article in MMWR. Morbidity and mortality weekly report, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Comparative Diagnostic Performance of Three Commercial Real-Time PCR Assays for the Detection of Mycobacterium tuberculosis Complex in Bronchial Washing Specimens: A Large Retrospective Study.Journal of clinical laboratory analysis · 2026Article
- Diagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing?Journal of clinical microbiology · 2025Article
- Wastewater-based surveillance as a tool for public health action: SARS-CoV-2 and beyond.Clinical microbiology reviews · 2024Review
- Advances in TB testing.Advances in clinical chemistry · 2023Article
- Description, validation, and review of a decade of experience with a laboratory-developed PCR test for detection ofJournal of clinical tuberculosis and other mycobacterial diseases · 2022Article
- Nucleic acid amplification tests reduce delayed diagnosis and misdiagnosis of pulmonary tuberculosis.Scientific reports · 2022Article
- The Brief Case: A Real Pain in the Testicle-a Case of Extrapulmonary Mycobacterium tuberculosis.Journal of clinical microbiology · 2022Review
- Assessing the utility of the Xpert Mycobacterium tuberculosis/rifampin assay for analysis of bronchoalveolar lavage fluid in patients with suspected pulmonary tuberculosis.Journal of clinical laboratory analysis · 2022Article
- Use of Nucleic Acid Amplification Testing for Rapid Detection ofOpen forum infectious diseases · 2021Article
- Effects of Coronavirus Disease Pandemic on Tuberculosis Notifications, Malawi.Emerging infectious diseases · 2021Article
- Rapid detection of tuberculosis in remote Alaska.International journal of circumpolar health · 2020Article
- Meeting the needs of CML patients in resource-poor countries.Hematology. American Society of Hematology. Education Program · 2019Review
- Impact of nucleic acid amplification test on pulmonary tuberculosis notifications and treatments in Taiwan: a 7-year single-center cohort study.BMC infectious diseases · 2019Article
- Design and Implementation of Data Exchange Formats for Molecular Detection of Drug-Resistant Tuberculosis.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2019Article
- Evaluation of EZplex MTBC/NTM Real-Time PCR kit: diagnostic accuracy and efficacy in vaccination.Clinical and experimental vaccine research · 2018Article
- Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria.Clinical microbiology reviews · 2018Review
- Molecular Diagnosis of Tuberculosis.Chonnam medical journal · 2018Review
- Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.Microbiology spectrum · 2017Review
- Role of the Health Department in Tuberculosis Prevention and Control-Legal and Public Health Considerations.Microbiology spectrum · 2017Review
- The new frontier of diagnostics: Molecular assays and their role in infection prevention and control.American journal of infection control · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In August 2013, the Food and Drug Administration (FDA) permitted marketing of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, California) to detect DNA of the Mycobacterium tuberculosis complex (MTBC) and genetic mutations associated with resistance to rifampin (RMP) in unprocessed sputum and concentrated sputum sediments. Along with clinical, radiographic, and other laboratory findings, results of the assay aid in the diagnosis of pulmonary tuberculosis (TB). The assay is a nucleic acid amplification-based (NAA)* test using a disposable cartridge in conjunction with the GeneXpert Instrument System. Sensitivity and specificity of the Xpert MTB/RIF assay for detection of MTBC appear to be comparable with other FDA-approved NAA assays for this use, although direct comparison studies have not been performed. Sensitivity of detection of RMP resistance was 95% and specificity 99% in a multicenter study using archived and prospective specimens from subjects aged ≥18 years suspected of having TB who had 0-3 days of antituberculous treatment. CDC continues to recommend following published U.S. guidelines for TB diagnosis and infection control practice, including the use and interpretation of NAA test results. Providers and laboratories need to ensure that specimens are available for other recommended mycobacteriological testing. The Xpert MTB/RIF assay aids in the prompt diagnosis of TB and RMP-resistant disease. RMP resistance most often coexists with isoniazid (INH) resistance; TB that is resistant to both drugs is multidrug-resistant (MDR)† TB. Because the prevalence of RMP resistance is low in the United States (about 1.8% of TB cases), a positive result indicating a mutation in the rpoB gene of MTBC should be confirmed by rapid DNA sequencing for prompt reassessment of the treatment regimen and followed by growth-based drug susceptibility testing (DST). CDC offers these services free of charge.§
Indexed as
Identifiers
24141407PMC4585342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.